The Lynx Group

April 2015, Vol 6, No 3

Orlando, FL—An independent review of the literature suggests that 3 biomarker tests developed for prostate cancer have yet to justify their utility in randomized clinical trials. The 3 tests in question—Prolaris, Decipher, and Oncotype DX for prostate cancer—are being used in practices around the country, cost approximately $3500 per test, and are reimbursable by Medicare depending on the state.
Read Article

Thyroid cancer, cancer that starts in the thyroid gland, accounts for 3.8% of all cancer cases in the United States.1 There were an estimated 62,980 new cases of thyroid cancer and 1890 deaths resulting from thyroid cancer in 2014.1 Thyroid cancer is most common in people aged 45 to 54 years (median age, 50 years),1 and it occurs 2 to 3 times more often in women than in men.2 The incidence of thyroid cancer has risen steadily in recent years.3 Although this increasing rate can be attributed largely to disease detection at an earlier stage, the incidence of larger tumors has also increased.3
Read Article

You have just been diagnosed with cancer, and one of the first people you meet on your healthcare team is introduced as a navigator. “A what?” you think. “I need doctors, not a GPS!” But over time, you will realize this person is a great guide.
Read Article

The recently released American Society of Clinical Oncology (ASCO) annual report, “The State of Cancer Care in America, 2015,” is a mixed bag: the report cites multiple advances in the progress against cancer, but also elaborates on the many hurdles in implementing state-of-the-art cancer care for all Americans.
Read Article


Chicago, IL—The National Cancer Institute (NCI) designation of a comprehensive cancer center trumps high case volume as a predictor of outcomes in ovarian cancer, according to a single-­region analysis.
Read Article

Chicago, IL—Poly (ADP-ribose) polymerase (PARP) inhibitor maintenance therapy with olaparib (Lynparza) for relapsed, platinum-sensitive ovarian cancer would meet conventional standards of cost-effectiveness only if the drug price decreased by ?66%, according to a modeling study.
Read Article

Chicago, IL—The addition of bevaciz­umab (Avastin) to standard chemotherapy extended survival in women with platinum-sensitive recurrent ovarian cancer compared with chemotherapy alone in the phase 3 randomized controlled GOG0213 trial. The results were presented at the 2015 Society of Gynecologic Oncology annual meeting.
Read Article


Hollywood, FL—The updated National Comprehensive Cancer Network (NCCN) guideline allows for the upfront use of docetaxel (Taxotere) in some men with castration-resistant prostate cancer (CRPC). This and other systemic therapies represent the most significant changes in the updated guideline for the treatment of patients with metastatic CRPC, said Andrew J. Armstrong, MD, ScM, Co­-Leader, Genitourinary Oncology Research Program, Duke Cancer Institute, Durham, NC, at the 2015 NCCN annual conference.
Read Article

Page 1 of 3

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: